OpenAI’s Fidji Simo Is Taking Medical Leave Amid an Executive Shake-Up
CEO of AGI deployment Fidji Simo steps back for health reasons amid major reorganization.
OpenAI is undergoing a significant executive reshuffle, with Fidji Simo, the CEO of AGI deployment, taking medical leave to address a relapse of a neuroimmune condition. In an internal note, Simo stated she had postponed medical care since joining the company in August 2025 and now requires several weeks for new interventions. President Greg Brockman will assume oversight of the product teams in her absence. The reorganization also sees Chief Operating Officer Brad Lightcap transitioning to a 'special projects' role, where he will lead the company's forward-deployed engineers who embed with enterprise clients.
Concurrently, Chief Marketing Officer Kate Rouch is taking a leave of absence while undergoing treatment for breast cancer. Upon her return, she will move into a different, more narrowly defined role, prompting OpenAI to begin a search for a new CMO. The company is also seeking a new chief communications officer. These leadership changes occur as OpenAI, recently valued at $852 billion after a record $122 billion funding round, streamlines its focus. Simo had recently shuttered the Sora social-video app to concentrate on core products like ChatGPT, signaling a strategic tightening ahead of a potential IPO later this year.
- Fidji Simo, CEO of AGI deployment, takes medical leave for a neuroimmune condition, with Greg Brockman taking over product oversight.
- COO Brad Lightcap moves to special projects, and CMO Kate Rouch is on leave for breast cancer treatment, with both roles being redefined.
- The shakeup comes as OpenAI, valued at $852B, refocuses on core products like ChatGPT ahead of a potential 2025 IPO.
Why It Matters
Leadership instability during a critical growth and IPO-prep phase could impact product strategy and enterprise client confidence.